CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Home Phototherapy Units — Coverage for Dermatologic Conditions

This policy governs coverage of home ultraviolet phototherapy devices for treatment of dermatologic conditions for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHome Phototherapy Units — Coverage for Dermatologic Conditions

Policy CodePolicy N/A

Change TypeMinor review — no material changes

Effective DateJun 21, 2021

Next Review DateN/A

Key ActionVerify member benefits and eligibility with the call center before billing; claims for home ultraviolet light therapy may be denied as a convenience service.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

E0691–E0694Referenced HCPCS

NonePrior auth

Coverage Criteria

Not Covered

Not covered when the following condition applies:

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Use of home-based psoralen plus ultraviolet A (PUVA) and other home ultraviolet light therapies for dermatologic conditions is excluded. The policy states that phototherapy in the home for the treatment of dermatological conditions is not covered because there is a lack of evidence that home-based PUVA or any other home-based ultraviolet light therapy is as safe or effective as office-based treatment; therefore home use is considered a convenience for the member and is not covered.

Home PUVA is considered not medically necessary primarily because regular, in-person monitoring and dose control cannot be ensured outside a clinical setting. Clinical guidance emphasizes that patients receiving a course of PUVA require regular assessments to determine treatment effectiveness and to detect adverse effects so that radiation exposure is kept to the minimum compatible with disease control. Because these essential evaluations are not reliably provided in the home setting, home PUVA is not medically necessary and is excluded as a covered service.

In addition to monitoring concerns, the policy describes the overall evidence base as insufficient: no studies were identified that directly compare home-based PUVA with office-based PUVA, and the available reviews note that home PUVA data are limited and require further validation. For these reasons, home phototherapy claims for ultraviolet light therapy may be denied as a convenience and providers should verify member-specific benefits under the subscriber agreement.

Coding

Covered/Referenced HCPCSHCPCS

E0691

Ultraviolet light therapy system, includes bulbs, timer and eye protection; treatment area 2 sq ft or less lamps

Not covered HCPCS codesHCPCSNot Covered

E0692	Ultraviolet light therapy system
E0693	Ultraviolet light therapy system panel, includes bulbs timer and eye protection, 6 ft 'lamps, panel
E0694	Ultraviolet multidirectional light in 6 ft cabinet; includes bulbs, timer, and eye protection therapy lamps, system

Provider Actions & Billing

Prior Authorization

Not applicable

Step Therapy

Step Therapy / Coverage Status

Phototherapy in the home for the treatment of dermatological conditions is not covered. There is a lack of evidence that home‑based PUVA or any other home‑based ultraviolet light therapy for treating dermatological conditions is as safe or effective as office‑based treatment. Therefore, use of this treatment in the home is considered a convenience for the member and is not covered.

Home phototherapy (including PUVA and other ultraviolet light therapies) is considered not covered regardless of prior treatments.

Note

Benefits Verification

Providers should verify member‑specific benefits and eligibility prior to providing services. Benefits and eligibility are determined by the member's subscriber agreement/member certificate and/or employer agreement; those documents supersede this medical policy.

Contact the payer/provider call center for member benefit and eligibility verification.
If services are determined to be not medically necessary or non‑covered, providers may not bill the member unless the member was informed and agreed in advance to pay out of pocket per participation agreements.

Denial Risk

Denial Risk for Home Phototherapy

Claims for home phototherapy may be denied because home use is considered a convenience and the service/device is categorized as not covered.

Denial risk applies to home phototherapy devices and services (including PUVA and other home ultraviolet therapies).
Verify coverage and obtain prior authorization where applicable for office‑based phototherapy procedures; home phototherapy should not be billed as covered.

Background

Home ultraviolet phototherapy units are devices designed for treatment of skin diseases that emit high-intensity, long-wave ultraviolet light and often contain multiple fluorescent lamps. These systems have been used for conditions such as psoriasis and chronic hand eczema, and some devices (for example, certain UVB systems) have received FDA 510(k) clearance for home use.

Despite device availability, PUVA (psoralen plus ultraviolet A) therapy—whether oral or otherwise—typically requires monitoring by trained clinical staff in an office setting because patients must be assessed regularly during a course of therapy to gauge effectiveness and to identify adverse effects. That monitoring ensures radiation dose is minimized while maintaining disease control.

Although some reports suggest oral PUVA at home can produce clinically relevant efficacy similar to hospital-administered PUVA and may reduce travel and time off work, the evidence is limited and lacks direct comparisons to office-based PUVA. Given the safety and monitoring concerns, the policy concludes that home-based PUVA and other home ultraviolet therapies are not supported as safe and effective alternatives to supervised, office-based phototherapy.

Definitions

Home phototherapy unit definition — device description and features

Termhome phototherapy unit

DescriptionA device designed for home treatment of skin diseases that usually contains multiple fluorescent lights emitting high-intensity, long-wave ultraviolet light; intended solely for medical treatment of dermatologic conditions.

Typical featuresMultiple fluorescent lamps delivering long-wave UV light, timers, and eye protection (device components described in coding group examples).

Regulatory exampleSome devices (e.g., Levia Personal Targeted Phototherapy UVB) received FDA 510(k) clearance for home use.

Clinical safety noteHome units require careful consideration because patients and many non-dermatologist physicians may not be trained to detect early skin cancer or other UV-related adverse effects.

PUVA definition — psoralen plus UVA therapy description and monitoring needs

TermPUVA (psoralen plus UVA)

DescriptionTherapy combining a psoralen photosensitizing agent with UVA radiation, administered orally or by other methods and requiring monitored UVA exposure.

Monitoring requirementsPatients must be assessed regularly during a course of PUVA to determine effectiveness and detect adverse effects, ensuring radiation exposure is minimized while controlling disease.

Setting recommendationPUVA is generally not recommended for home use because monitoring and dose control comparable to office-based administration cannot be ensured; therapy should be administered in the dermatologist's office with trained staff and monitored UVA machines.

Evidence summarySome trials (e.g., oral PUVA with portable unit for chronic hand eczema) showed comparable efficacy to hospital-administered PUVA, but no studies directly compared home-based PUVA with office-based PUVA and additional research is needed.